Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.

ABSTRACT:

Aims

To evaluate the associations of treatment and an additive genetic efficacy score (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled into two randomized clinical trials of smoking cessation therapies.

Design

Double-blind pharmacogenetic efficacy trials randomizing participants to active or placebo bupropion. Study 1 also randomized participants to cognitive-behavioral smoking cessation treatment (CBT) or this treatment with CBT for depression. Study 2 provided standardized behavioural support.

Setting

Two hospital-affiliated clinics (study 1), and two university-affiliated clinics (study 2).

Participants

A total of 792 self-identified white treatm

SUBMITTER: David SP 

PROVIDER: S-EPMC3834197 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature